Four epigenetic clocks moved. Thirty-two weeks, 84 adults, weekly semaglutide titrated to one milligram against placebo, double-blind.

DunedinPACE fell 0.09 units, which reads as a pace of aging roughly nine percent slower (p=0.01). PhenoAge fell 4.90 years (p=0.004), PCGrimAge 3.08 (p=0.007), GrimAge V2 2.26 (p=0.008), GrimAge V1 1.39 (p=0.042).

That is the strongest randomised evidence to date that a drug already sitting in a lot of Singapore fridges moves a methylation clock.

The protocol is worth naming, because it is smaller than the one being marketed. Semaglutide at 0.25 milligrams weekly for four weeks, up to 0.5, then held at 1.0 milligram a week through week 32. No diet arm, no training arm, no stack.

Now the parts the headlines dropped. The arms were 45 on drug and 39 on placebo, all of them adults with HIV-associated lipohypertrophy, a specific metabolic problem in a specific patient group. The epigenetic work is a post hoc analysis of a phase 2b trial built to measure something else, and the authors call it limited by sample size and short follow-up.

Three more clocks went nowhere. AdaptAge, CausAge and DamAge returned heterogeneous, non-significant results across the same samples.

And the Intrinsic Capacity clock, the one built to track how well a body still works, did not shift at all (p=0.31).

What moved were the clocks trained to predict death. What stayed flat was the clock aimed at function.

That gap is the disclosure worth holding on to. What moved were the clocks trained to predict death. What stayed flat was the clock aimed at function.

Which matters because movement on the first kind is what the premium longevity aisle sells. A package that hands back a biological age two years lower is handing back a methylation estimate, and this trial is a good calibration for what that estimate is worth: real enough to reach p=0.004 in a randomised design, thin enough that the people who ran it will not call the drug an anti-aging drug, and silent on whether the body carrying the number climbs more stairs at sixty.

Michael Corley, who led the analysis at UC San Diego, said it in the plainest available words. They are not saying semaglutide reverses aging or makes people younger.

The Singapore development landed five days ahead of the paper and pointed somewhere else entirely. On 8 July, Novo Nordisk updated the Wegovy label here to carry the 7.2 milligram dose, on STEP UP data showing mean weight loss of 21 percent over 72 weeks with up to 84 percent of that coming off as fat mass.

The approved indication is unchanged. Weight management at a BMI of 30, or 27 with a weight-related condition.

Seven point two milligrams is seven times the dose that moved the clocks.

Seven point two milligrams is seven times the dose that moved the clocks.

Nobody has run the aging analysis at that dose, in people without HIV-associated lipohypertrophy, past eight months. That trial is what would carry this from a signal to a finding, and it has not been run. Anyone weighing a prescription is weighing it with a doctor, on the indication it was approved for, and this piece reports a measurement rather than a course of action.

The number to watch in the next round is the one that stayed still. On a drug that slowed aging rather than the markers of it, Intrinsic Capacity would have to move too.